Pulmatrix (NSDQ:PULM) said yesterday that it dosed the first patient in its Phase II trial of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis asthmatics.
The 64-patient study is a randomized, double-blinded, placebo-controlled trial to evaluate the safety and efficacy of three dose levels of the anti-fungal drug itraconazole formulation Pulmazole.
The multi-center, four-arm trial will be randomized to receive 10mg, 20mg or 35mg of Pulmazole or placebo, administered by dry powder inhalation once daily. The study’s primary objective is to evaluate the safety and tolerability of Pulmazole in adult subjects with asthma and ABPA.
Get the full story at our sister site, Drug Delivery Business News.
